QURE Soars on FDA Alignment for Speedy Approval of Huntington's Drug
Qure stock rallies 110% on reaching alignment with the FDA on key elements of an accelerated approval pathway for AMT-130 to ...
Biotech Stock Roundup: BIOA Down on Study Update, QURE, CRDF Gain on Study Data & More
It was a busy week in the biotech sector with lots of data readouts. This apart, the key regulatory updates and pipeline news also continued to be in the spotlight.
pharmaphorum20h
uniQure rockets on map to market for Huntington's therapy
Crucially for the Netherlands-based biopharma company, the FDA has said that the composite Unified Huntington's Disease ...
StockNews.com Upgrades uniQure (NASDAQ:QURE) to “Sell”
Qure (NASDAQ:QURE – Get Free Report) was upgraded by research analysts at StockNews.com to a “sell” rating in a research note issued to investors on Wednesday. Other research analysts have also ...
uniQure (NASDAQ:QURE) Shares Sold by Verition Fund Management LLC
Verition Fund Management LLC lowered its position in uniQure (NASDAQ:QURE – Free Report) by 77.9% during the third quarter, ...
BioSpace18h
Highlights From ASH, Lilly and Novo’s Manufacturing Boon, Momentum in Neuro, More
GSK, Gilead and Arcellx, Vertex and more present new data at the American Society of Hematology annual meeting just as sickle cell therapies Casgevy and Lyfgenia have a new outcomes-based payment ...
The Pharma Letter17h
Huge backing for Noema’s neuroscience goal
Noema Pharma, a Swiss biotech targeting debilitating central nervous system (CNS) disorders, has announced the successful ...